Quick Answer
ArriVent BioPharma, Inc. reported Cash And Cash Equivalents At Carrying Value of $45.54 million for the year ending 2025.
- ArriVent BioPharma, Inc. showed a decrease of -38.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from ArriVent BioPharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $317.39 million | Q2 2024: $298.67 million | Q3 2024: $282.86 million | Q1 2025: $49.87 million | Q2 2025: $112.77 million | Q3 2025: $112.67 million.
- Over the full 3 years of available data (2023 to 2025), ArriVent BioPharma, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 69.7%.
- Historical annual values: Fiscal year 2025: $45.54 million | Fiscal year 2024: $74.29 million | Fiscal year 2023: $150.39 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: